Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

(2020) Yin‐Xiao Du et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pathogenesis of COVID-19 from a cell biology perspective

(2020) Robert J. Mason   EUROPEAN RESPIRATORY JOURNAL

COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

(2020) Hasan K. Siddiqi et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID‐19)

(2020) J. Wu et al.   JOURNAL OF INTERNAL MEDICINE

Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)

(2020) Prakhar Vijayvargiya et al.   MAYO CLINIC PROCEEDINGS

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

(2020) Qingxian Cai et al.   Engineering

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

(2020) Andrey A Ivashchenko et al.   CLINICAL INFECTIOUS DISEASES

The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance

(2020) Marco Tuccori et al.   DRUG SAFETY

Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic?

(2020) Daniele Giammaria et al.   Journal of Global Health

A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19

(2020) Yohei Doi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV2 Infection (COVID-19)

(2020) Peter A. McCullough   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective

(2020) Joshua Adedeji Bolarin et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2

(2020) Arif Kivrak et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

(2016) Daouda Sissoko et al.   PLOS MEDICINE